Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication, By Region, And Segment- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

The global advanced therapy medicinal products CDMO market size was estimated at USD 6.10 billion in 2023 and is projected to hit around USD 34.53 billion by 2033, growing at a CAGR of 18.93% during the forecast period from 2024 to 2033.

Advanced Therapy Medicinal Products CDMO Market Size, 2024 to 2033

Key Takeaways:

  • North America dominated the overall market share of 49.11% in 2023.
  • The U.S. accounted for the largest share of the global market in the North America region in 2023.
  • The Asia Pacific region is expected to grow at the fastest CAGR over the forecast period
  • The gene therapy segment held the largest share of over 49.11% in 2023.
  • The cell therapy segment is expected to show lucrative growth over the forecast period.
  • The oncology segment accounted for the largest revenue share in 2023.
  • The cardiology segment is estimated to register the fastest CAGR over the forecast period.
  • The phase I segment dominated the market in 2023
  • The phase II segment has been anticipated to show lucrative growth over the forecast period.

Advanced Therapy Medicinal Products CDMO Market Growth

The growth of the market is attributed to factors such as the rising demand for advanced therapy, rising number of clinical trials for ATMPs and growing number of treatments. Moreover, increased investment in research and developments of advanced therapy pharmaceutical products, as well as an increase in the prevalence of rare and severe disorders including metabolic and optical diseases.

The COVID-19 pandemic has had a massive impact on the development and manufacturing of advanced therapy medicinal products. Cell-based therapy was one of the fastest growing classes of medicines during the COVID-19 pandemics. The USA, Jordan, China, Iran, and several other nations started cell-based therapy clinical research to treat COVID-19 individuals with acute respiratory distress at the same time that the disease was spreading over the world. For instance, more than 80 clinical trials had been registered as of 2022, according to a search on ClinicalTrials.gov for "Mesenchymal stem cells and COVID-19.

One of the major drivers of the market is the increasing number of clinical trials for ATMPs. According to the American Society of Gene and Cell Therapy report, as of Q1 2022, 3,579 therapies are in the pipeline of gene, cell, and RNA therapies. As per a report, the gene cell therapy pipeline has increased by 16% as of Q1 2021. In the pipeline, CAR-T cell therapies are dominating genetically modified cell therapies. Moreover, 98% of CAR-T cell therapies are in the development phase for cancer indication. In addition to it, in August 2023, the European Commission declared financial support for combined Advanced Therapy Medicinal Products (ATMPs) by earmarking funding specifically for Phase 2 clinical trials and subsequent stages.

Furthermore, outsourcing activities in this domain are rising, as this strategy enables companies to acquire additional competencies required for successful development and commercialization of ATMPs. Apart from offering extended expertise and aiding in better management of cash flows, outsourcing provides significant manufacturing advantages, such as a reduction in investment risks. In addition, low incidence-to-prevalence ratios for genetic and rare diseases make outsourcing an attractive option, as the construction of in-house facility for producing a single gene therapy for these diseases requires a faster cost recovery in a short time frame.

Moreover, increasing competition among the key companies to gain considerable market share in the field is expected to boost R&D investment flow in the market. For Instance, in January 2022, Excellos, a cell therapy CDMO, announced the launch and closing of USD 15 million in funding from Telegraph Hill Partners. The company is engaged in supplying cGMP cellular Cell Therapy and products, with manufacturing and process development expertise to clinicians and scientists working with cell and gene therapies.

Advanced Therapy Medicinal Products CDMO Market Report Scope

Report Attribute Details
Market Size in 2024 USD 7.25 Billion
Market Size by 2033 USD 34.53 Billion
Growth Rate From 2024 to 2033 CAGR of 18.93%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Product, phase, indication, region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled Celonic; Bio Elpida; CGT Catapult; Rentschler Biopharma SE; AGC Biologics; Catalent; Lonza; WuXi Advanced Therapies; BlueReg; Minaris Regenerative Medicine; Patheon

 

Segments Insights:

Product Insights

The gene therapy segment held the largest share of over 49.11% in 2023. Increase in financial support and rise in number of clinical trials for gene therapies are driving demand for gene therapy segment. In 2020, in the first three quarters, gene therapies attracted financing of over USD 12 billion globally, with around 370 clinical trials underway. Additionally, in mid-2022, approximately 2,000 gene therapies were in development, targeting several therapeutic areas, such as neurological, cancer, cardiovascular, blood, and infectious diseases.

The cell therapy segment is expected to show lucrative growth over the forecast period. The field of cellular therapeutics is constantly advancing with inclusion of new cell types, which, in turn, provides ample opportunities for companies to enhance their market positions. Furthermore, the market is attracting new entrants due to high unmet demand for cell therapy manufacturing, the recent approval of advanced therapies, and proven effectiveness of these products.

Indication Insights

The oncology segment accounted for the largest revenue share in 2023. The segment’s dominance is attributed to disease burden, strategic initiatives undertaken by key players, and availability of advanced therapies used for treating various cancer indications. In January 2021, around 18,000 to 19,000 patients and 124,000 patients were estimated to be potential patients for treating cancer using cell & gene therapy products Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.), respectively. Furthermore, a publication on PubMed reports that as of the conclusion of the first quarter of 2023, there have been over 100 distinct gene, cell, and RNA therapies approved globally, along with an additional 3,700-plus in various stages of clinical and preclinical development.

The cardiology segment is estimated to register the fastest CAGR over the forecast period. This is attributed to the increasing prevalence of cardiovascular diseases and research collaboration for development of advanced therapies. For instance, in October 2023, Cleveland Clinic administered a novel gene therapy to the first patient globally as part of a clinical trial, aiming to deliver a functional gene to combat the primary cause of hypertrophic cardiomyopathy (HCM). Similarly, in February 2021, Trizell GmbH entered into partnership with Catalent, Inc. for development of phase 1 cell therapy to treat micro- and macroangiopathy. Trizell's medication is an Advanced Therapy Medicinal Product (ATMP) that employs regulatory macrophages—a platform technology developed in Germany.

Phase Insights

The phase I segment dominated the market in 2023 due to growing R&D activities and increasing number of human trials for advanced therapies. Phase 1 helps ensure the safety levels of a drug at different doses and dosage forms administered to a small number of patients. This phase is mainly conducted to determine the highest dose a patient can take without any adverse effects. Around 70% of drugs in phase 1 move to the next phase.

The phase II segment has been anticipated to show lucrative growth over the forecast period. Phase II clinical studies comprise the largest number of developing ATMPs, due to the high clearance rate of phase I clinical studies. According to data published by Alliance for Regenerative Medicine, as of June 2022, more than 2,093 clinical trials are ongoing globally, out of which 1,117 are under phase II clinical trials accounting for 53%. Thus, the increase in number of products in phase II is driving the segment.

Regional Insights

North America dominated the overall market share of 49.11% in 2023. This can be attributed to increasing outsourcing activities and rising awareness about advanced therapy. North America has consistently been a leader in R&D for advanced treatments, and it is anticipated that it will keep this position during the forecast period. Recent approvals of products such as Kymriah and Yescarta have propelled investments in the regional market. Moreover, in March 2021, the U.S. FDA approved Abecma, the first approval of CAR-T cells to fight against cancer. Similarly, in December 2023, Casgevy and Lyfgenia, the initial cell-based gene therapies for sickle cell disease (SCD) in patients aged 12 and above, received approval from the U.S. Food and Drug Administration, marking a significant milestone.

The U.S. accounted for the largest share of the global market in the North America region in 2023. The U.S. maintains dominance in this sector due to the presence of a robust and highly advanced biopharmaceutical industry with a considerable focus on research and development. Additionally, the continuous presence of numerous pharmaceutical and biotechnology companies, along with academic and research institutions, generates a sustained demand for rigorous safety testing, further reinforcing the country's leadership in the field.

The Asia Pacific region is expected to grow at the fastest CAGR over the forecast period due to the increasing demand for novel ATMPs and rising R&D activities to develop novel therapies. Moreover, the market growth is driven by continuously expanding CDMO Cell Therapy in the country, a number of domestic players have collaborated with biotech companies from other countries involved in mesenchymal stem cell research and therapy development. In addition, in September 2022 Takara Bio, Inc. launched CDMO Cell Therapy for gene therapy products using siTCR technology for its genetically modified T-cell therapy products.

China accounted for the largest share of the global market in the Asia Pacific region in 2023 due to its strategic focus on advancing research and development capabilities, particularly in the pharmaceutical and biotechnology sectors. Additionally, with a rapidly growing biopharmaceutical industry and supportive government initiatives, China has become a key market for advanced therapy medicinal products (CDMO) market.

Recent Developments

  • In July 2023, The US FDA approved the Investigational New Drug (IND) application for NTLA-2001, marking the clearance for the first-ever CRISPR-based gene therapy designed for in vivo treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.
  • In December 2023, the US FDA granted approval for two gene-based treatments for sickle cell disease, marking a significant milestone. Notably, one of these therapies represents the first application of the gene-editing technique CRISPR in the treatment of the disease.
  • In February 2022, Recipharm AB completed the acquisition of Vibalogics. With this agreement, Recipharm will obtain expertise in biologics modalities, utilizing Vibalogics' capability in viral vaccines, oncolytic viruses, and viral vector gene treatments to deliver high level of diversification through several technologies and modalities.
  • In April 2022, Pfizer announced the opening of its unit for phase III trial of investigational gene therapy for patients with Duchenne muscular dystrophy.

Key Companies & Market Share Insights

Some of the key players operating in the market include AGC Biologics,WuXi Advanced Therapies and Celonic

  • AGC Biologics offers a range of Cell Therapy for advanced therapy medicinal products (ATMPs), including gene and cell therapies.AGC Biologics specializes in the development and manufacturing of protein-based biologics and advanced therapies, including cell therapy, viral vectors, and mammalian and microbial cell therapy.
  • WuXi AppTec provides a comprehensive range of analytical testing Cell Therapy to characterize complex biologics, vaccines, and advanced therapies.

Minaris Regenerative Medicine and BlueReg are some of the emerging market players in the global market.

  • Minaris Regenerative Medicine offers a wide range of cell types, manufacturing technologies, and procedures, analytical methods, and regulatory expertise.

Key Advanced Therapy Medicinal Products CDMO Companies:

  • Celonic
  • Bio Elpida
  • CGT Catapult
  • Rentschler Biopharma SE
  • AGC Biologics
  • Catalent
  • Lonza
  • WuXi Advanced Therapies
  • BlueReg
  • Minaris Regenerative Medicine
  • Patheon

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Advanced Therapy Medicinal Products CDMO market.

By Product 

  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered
  • Others

By Phase 

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication 

  • Oncology
  • Cardiology
  • Central nervous system
  • Musculoskeletal
  • Infectious disease
  • Dermatology
  • Endocrine, metabolic, genetic
  • Immunology & inflammation
  • Ophthalmology
  • Hematology
  • Gastroenterology
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global advanced therapy medicinal products CDMO market size was estimated at USD 6.10 billion in 2023 and is projected to hit around USD 34.53 billion by 2033

Key factors driving the advanced therapy medicinal products CDMO market growth include increasing prevalence of rare & life-threatening diseases, rising investment in R&D of advanced therapy medicinal products, and increasing outsourcing activities.

Some key players operating in the advanced therapy medicinal products CDMO market include Celonic, Bio Elpida, CGT Catapult, Rentschler Biopharma SE, AGC Biologics, Catalent, Lonza, WuXi Advanced Therapies, BlueReg, Minaris Regenerative Medicine, Patheon

The global advanced therapy medicinal products CDMO market is expected to grow at a compound annual growth rate of 18.93% from 2024 to 2033

Chapter 1. Methodology And Scope
                   1.1. Market Segmentation And Scope
                       1.1.1. Segment Definitions
                           1.1.1.1. Product Segment
                           1.1.1.2. Phase Segment
                           1.1.1.3. Indication Segment
                   1.2. Regional Scope
                   1.3. Estimates And Forecast Timeline
                   1.4. Objectives
                       1.4.1. Objective - 1
                       1.4.2. Objective - 2
                   1.5. Research Methodology
                   1.6. Information Procurement
                       1.6.1. Purchased Database
                       1.6.2. Nova one advisor Internal Database
                       1.6.3. Secondary Sources
                       1.6.4. Primary Research
                   1.7. Information or Data Analysis
                       1.7.1. Data Analysis Models
                   1.8. Market Formulation & Validation
                   1.9. Model Details
                       1.9.1. Commodity Flow Analysis
                   1.10. List Of Primary Sources
                   1.11. List Of Abbreviations
Chapter 2. Advanced Therapy Medicinal Products CDMO Market: Executive Summary
                   2.1. Market Snapshot
                   2.2. Products Snapshots
                   2.3. Phase Snapshots
                   2.4. Indication Snapshot
                   2.5. Competitive Landscape Snapshot
Chapter 3. Advanced Therapy Medicinal Products CDMO Market Variables, Trends, & Scope
                   3.1. Market Segmentation And Scope
                   3.2. Market Lineage Outlook
                       3.2.1. Parent Market Outlook
                       3.2.2. Related/Ancillary Market Outlook
                   3.3. Market Dynamics
                   3.4. Market Drivers Analysis
                       3.4.1. Rising number of clinical trials for ATMPs
                       3.4.2. Increasing outsourcing activities
                       3.4.3. Growing awareness of the treatment
                   3.5. Market Restraint Analysis
                       3.5.1. Stringent regulatory approvals
                       3.5.2. High cost of outsourcing
                   3.6. Advanced Therapy Medicinal Products CDMO Market Analysis Tools
                       3.6.1. Industry Analysis - Porter’s
                           3.6.1.1. Supplier Power
                           3.6.1.2. Buyer Power
                           3.6.1.3. Substitution Threat
                           3.6.1.4. Threat Of New Entrant
                           3.6.1.5. Competitive Rivalry
                       3.6.2. PESTLE Analysis
                           3.6.2.1. Political Landscape
                           3.6.2.2. Technological Landscape
                           3.6.2.3. Economic Landscape
Chapter 4. Advanced Therapy Medicinal Products CDMO: Products Estimates & Trend Analysis
                   4.1. Product Market Share, 2023 & 2030
                   4.2. Segment Dashboard
                   4.3. Global Advanced Therapy Medicinal Products CDMO Market, By Product Outlook
                   4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
                       4.4.1. Gene Therapy
                           4.4.1.1. Market Estimates And Forecasts, 2020 To 2033
                       4.4.2. Cell Therapy
                           4.4.2.1. Market Estimates And Forecasts, 2020 To 2033
                       4.4.3. Tissue Engineered
                           4.4.3.1. Market Estimates And Forecasts, 2020 To 2033
                       4.4.4. Others
                           4.4.4.1. Market Estimates And Forecasts, 2020 To 2033
Chapter 5. Advanced Therapy Medicinal Products CDMO: Phase Estimates & Trend Analysis
                   5.1. Phase Market Share, 2023 & 2030
                   5.2. Segment Dashboard
                   5.3. Global Advanced Therapy Medicinal Products CDMO Market, By Phase Outlook
                   5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
                       5.4.1. Phase I
                           5.4.1.1. Market Estimates And Forecasts, 2020 To 2033
                       5.4.2. Phase II
                           5.4.2.1. Market Estimates And Forecasts, 2020 To 2033
                       5.4.3. Phase III
                           5.4.3.1. Market Estimates And Forecasts, 2020 To 2033
                       5.4.4. Phase IV
                           5.4.4.1. Market Estimates And Forecasts, 2020 To 2033
Chapter 6. Advanced Therapy Medicinal Products CDMO: Indication Estimates & Trend Analysis
                   6.1. Indication Market Share, 2023 & 2030
                   6.2. Segment Dashboard
                   6.3. Global Advanced Therapy Medicinal Products CDMO Market, By Indication Outlook
                   6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
                       6.4.1. Oncology
                           6.4.1.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.2. Cardiology
                           6.4.2.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.3. Central Nervous System
                           6.4.3.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.4. Musculoskeletal
                           6.4.4.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.5. Infectious Disease
                           6.4.5.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.6. Dermatology
                           6.4.6.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.7. Endocrine, Metabolic, Genetic
                           6.4.7.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.8. Immunology & Inflammation
                           6.4.8.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.9. Ophthalmology
                           6.4.9.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.10. Hematology
                           6.4.10.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.11. Gastroenterology
                           6.4.11.1. Market Estimates And Forecasts, 2020 To 2033
                       6.4.12. Others
                           6.4.12.1. Market Estimates And Forecasts, 2020 To 2033
Chapter 7. Regional Business Analysis
                   7.1. Regional Market Share Analysis, 2023 & 2030
                   7.2. Regional Market Dashboard
                   7.3. Global Regional Market Snapshot
                   7.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
                   7.5. North America
                       7.5.1. U.S.
                           7.5.1.1. Key Country Dynamics
                           7.5.1.2. Competitive Scenario
                           7.5.1.3. Regulatory Framework
                           7.5.1.4. U.S. Market Estimates And Forecasts, 2020 To 2033
                       7.5.2. Canada
                           7.5.2.1. Key Country Dynamics
                           7.5.2.2. Competitive Scenario
                           7.5.2.3. Regulatory Framework
                           7.5.2.4. Canada Market Estimates And Forecasts, 2020 To 2033
                   7.6. Europe
                       7.6.1. UK
                           7.6.1.1. Key Country Dynamics
                           7.6.1.2. Competitive Scenario
                           7.6.1.3. Regulatory Framework
                           7.6.1.4. UK Market Estimates And Forecasts, 2020 To 2033
                       7.6.2. Germany
                           7.6.2.1. Key Country Dynamics
                           7.6.2.2. Competitive Scenario
                           7.6.2.3. Regulatory Framework
                           7.6.2.4. Germany Market Estimates And Forecasts, 2020 To 2033
                       7.6.3. Spain
                           7.6.3.1. Key Country Dynamics
                           7.6.3.2. Competitive Scenario
                           7.6.3.3. Regulatory Framework
                           7.6.3.4. Spain Market Estimates And Forecasts, 2020 To 2033
                       7.6.4. France
                           7.6.4.1. Key Country Dynamics
                           7.6.4.2. Competitive Scenario
                           7.6.4.3. Regulatory Framework
                           7.6.4.4. France Market Estimates And Forecasts, 2020 To 2033
                       7.6.5. Italy
                           7.6.5.1. Key Country Dynamics
                           7.6.5.2. Competitive Scenario
                           7.6.5.3. Regulatory Framework
                           7.6.5.4. Italy Market Estimates And Forecasts, 2020 To 2033
                       7.6.6. Denmark
                           7.6.6.1. Key Country Dynamics
                           7.6.6.2. Competitive Scenario
                           7.6.6.3. Regulatory Framework
                           7.6.6.4. Denmark Market Estimates And Forecasts, 2020 To 2033
                       7.6.7. Sweden
                           7.6.7.1. Key Country Dynamics
                           7.6.7.2. Competitive Scenario
                           7.6.7.3. Regulatory Framework
                           7.6.7.4. Sweden Market Estimates And Forecasts, 2020 To 2033
                       7.6.8. Norway
                           7.6.8.1. Key Country Dynamics
                           7.6.8.2. Competitive Scenario
                           7.6.8.3. Regulatory Framework
                           7.6.8.4. Norway Market Estimates And Forecasts, 2020 To 2033
                   7.7. Asia Pacific
                       7.7.1. Japan
                           7.7.1.1. Key Country Dynamics
                           7.7.1.2. Competitive Scenario
                           7.7.1.3. Regulatory Framework
                           7.7.1.4. Japan Market Estimates And Forecasts, 2020 To 2033
                       7.7.2. China
                           7.7.2.1. Key Country Dynamics
                           7.7.2.2. Competitive Scenario
                           7.7.2.3. Regulatory Framework
                           7.7.2.4. China Market Estimates And Forecasts, 2020 To 2033
                       7.7.3. India
                           7.7.3.1. Key Country Dynamics
                           7.7.3.2. Competitive Scenario
                           7.7.3.3. Regulatory Framework
                           7.7.3.4. India Market Estimates And Forecasts, 2020 To 2033
                       7.7.4. South Korea
                           7.7.4.1. Key Country Dynamics
                           7.7.4.2. Competitive Scenario
                           7.7.4.3. Regulatory Framework
                           7.7.4.4. South Korea Market Estimates And Forecasts, 2020 To 2033
                       7.7.5. Thailand
                           7.7.5.1. Key Country Dynamics
                           7.7.5.2. Competitive Scenario
                           7.7.5.3. Regulatory Framework
                           7.7.5.4. Thailand Market Estimates And Forecasts, 2020 To 2033
                       7.7.6. Australia
                           7.7.6.1. Key Country Dynamics
                           7.7.6.2. Competitive Scenario
                           7.7.6.3. Regulatory Framework
                           7.7.6.4. Australia Market Estimates And Forecasts, 2020 To 2033
                   7.8. Latin America
                       7.8.1. Brazil
                           7.8.1.1. Key Country Dynamics
                           7.8.1.2. Competitive Scenario
                           7.8.1.3. Regulatory Framework
                           7.8.1.4. Brazil Market Estimates And Forecasts, 2020 To 2033
                       7.8.2. Mexico
                           7.8.2.1. Key Country Dynamics
                           7.8.2.2. Competitive Scenario
                           7.8.2.3. Regulatory Framework
                           7.8.2.4. Mexico Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
                       7.8.3. Argentina
                           7.8.3.1. Key Country Dynamics
                           7.8.3.2. Competitive Scenario
                           7.8.3.3. Regulatory Framework
                           7.8.3.4. Argentina Market Estimates And Forecasts, 2020 To 2033
                   7.9. MEA
                       7.9.1. MEA Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
                       7.9.2. South Africa
                           7.9.2.1. Key Country Dynamics
                           7.9.2.2. Competitive Scenario
                           7.9.2.3. Regulatory Framework
                           7.9.2.4. South Africa Market Estimates And Forecasts, 2020 To 2033
                       7.9.3. Saudi Arabia
                           7.9.3.1. Key Country Dynamics
                           7.9.3.2. Competitive Scenario
                           7.9.3.3. Regulatory Framework
                           7.9.3.4. Saudi Arabia Market Estimates And Forecasts, 2020 To 2033
                       7.9.4. UAE
                           7.9.4.1. Key Country Dynamics
                           7.9.4.2. Competitive Scenario
                           7.9.4.3. Regulatory Framework
                           7.9.4.4. UAE Market Estimates And Forecasts, 2020 To 2033
                       7.9.5. Kuwait
                           7.9.5.1. Key Country Dynamics
                           7.9.5.2. Competitive Scenario
                           7.9.5.3. Regulatory Framework
                           7.9.5.4. Kuwait Market Estimates And Forecasts, 2020 To 2033
Chapter 8. Competitive Landscape
                   8.1. Recent Developments & Impact Analysis, By Key Market Participants
                   8.2. Company /Competition Categorization
                   8.3. Vendor Landscape
                       8.3.1. List Of Key Distributors And Channel Partners
                       8.3.2. Key Customers
                       8.3.3. Key Company Market Share Analysis, 2023
                       8.3.4. CELONIC Group
                           8.3.4.1. Overview
                           8.3.4.2. Financial Performance
                           8.3.4.3. Product Benchmarking
                           8.3.4.4. Strategic Initiatives
                       8.3.5. Bio Elpida
                           8.3.5.1. Overview
                           8.3.5.2. Financial Performance
                           8.3.5.3. Product Benchmarking
                           8.3.5.4. Strategic Initiatives
                       8.3.6. Rentschler Biopharma SE
                           8.3.6.1. Overview
                           8.3.6.2. Financial Performance
                           8.3.6.3. Product Benchmarking
                           8.3.6.4. Strategic Initiatives
                       8.3.7. AGC Biologics
                           8.3.7.1. Overview
                           8.3.7.2. Financial Performance
                           8.3.7.3. Product Benchmarking
                           8.3.7.4. Strategic Initiatives
                       8.3.8. Catalent, Inc.
                           8.3.8.1. Overview
                           8.3.8.2. Financial Performance
                           8.3.8.3. Product Benchmarking
                           8.3.8.4. Strategic Initiatives
                       8.3.9. Lonza
                           8.3.9.1. Overview
                           8.3.9.2. Financial Performance
                           8.3.9.3. Product Benchmarking
                           8.3.9.4. Strategic Initiatives
                       8.3.10. Wuxi Advanced Therapies
                           8.3.10.1. Overview
                           8.3.10.2. Financial Performance
                           8.3.10.3. Product Benchmarking
                           8.3.10.4. Strategic Initiatives
                       8.3.11. Minaris Regenerative Medicine
                           8.3.11.1. Overview
                           8.3.11.2. Financial Performance
                           8.3.11.3. Product Benchmarking
                           8.3.11.4. Strategic Initiatives
                       8.3.12. Patheon, Inc.
                           8.3.12.1. Overview
                           8.3.12.2. Financial Performance
                           8.3.12.3. Product Benchmarking
                           8.3.12.4. Strategic Initiatives
                       8.3.13. CGT Catapult
                           8.3.13.1. Overview
                           8.3.13.2. Financial Performance
                           8.3.13.3. Product Benchmarking
                           8.3.13.4. Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert